{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:57:09Z","timestamp":1790009829512,"version":"4.0.1"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,11,29]],"date-time":"2014-11-29T00:00:00Z","timestamp":1417219200000},"content-version":"vor","delay-in-days":1369,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100009930","name":"Basilea Pharmaceutica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009930","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1111\/j.1469-0691.2010.03448.x","type":"journal-article","created":{"date-parts":[[2011,1,20]],"date-time":"2011-01-20T19:38:33Z","timestamp":1295552313000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"S1","title":["Anidulafungin for the treatment of invasive candidiasis"],"prefix":"10.1016","volume":"17","author":[{"given":"A.","family":"Mayr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Aigner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lass-Fl\u00f6rl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/j.1469-0691.2010.03448.x_bib1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ijantimicag.2009.03.014","article-title":"Consensus statement on the management of invasive candidiasis in intensive care units in the Asia-Pacific Region","volume":"34","author":"Hsueh","year":"2009","journal-title":"Int J Antimicrob Agents"},{"issue":"suppl 2","key":"10.1111\/j.1469-0691.2010.03448.x_bib2","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/S0924-8579(08)70006-2","article-title":"Mu\u00f1oz P. Epidemiology of candidemia in intensive care units","volume":"32","author":"Bouza","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib3","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/jac\/dkp251","article-title":"Incidence of candidaemia and relationship with fluconazole use in an intensive care unit","volume":"64","author":"Bassetti","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib4","first-page":"453","article-title":"Invasive candidiasis and candidemia: new guidelines","volume":"75","author":"De Rosa","year":"2009","journal-title":"Minerva Anestesiol"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00134-008-1338-7","article-title":"Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: part I. Epidemiology and diagnosis","volume":"35","author":"Guery","year":"2009","journal-title":"Intensive Care Med"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib6","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1086\/599039","article-title":"Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry","volume":"48","author":"Horn","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib7","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/596757","article-title":"Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America","volume":"48","author":"Pappas","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib8","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1439-0507.2009.01691.x","article-title":"The changing face of epidemiology of invasive fungal disease in Europe","volume":"52","author":"Lass-Fl\u00f6rl","year":"2009","journal-title":"Mycoses"},{"issue":"suppl 1","key":"10.1111\/j.1469-0691.2010.03448.x_bib9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2165\/11315500-000000000-00000","article-title":"Epidemiology, incidence and risk factors for invasive candidiasis in high-risk patients","volume":"69","author":"Concia","year":"2009","journal-title":"Drugs"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib10","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1086\/421946","article-title":"Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study","volume":"39","author":"Wisplinghoff","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib11","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.ijantimicag.2006.01.002","article-title":"Candidaemia in Europe: epidemiology and resistance","volume":"27","author":"Tortorano","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10096-004-1103-y","article-title":"Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study","volume":"23","author":"Tortorano","year":"2004","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1128\/CMR.00029-06","article-title":"Epidemiology of invasive candidiasis: a persistent public health problem","volume":"20","author":"Pfaller","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib14","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1128\/JCM.43.4.1829-1835.2005","article-title":"Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003","volume":"43","author":"Almirante","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib15","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1128\/JCM.43.9.4434-4440.2005","article-title":"Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility","volume":"43","author":"Arendrup","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib16","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1128\/JCM.40.9.3489-3492.2002","article-title":"Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland","volume":"40","author":"Asmundsd\u00f3ttir","year":"2002","journal-title":"J Clin Microbiol"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib17","doi-asserted-by":"crossref","first-page":"985","DOI":"10.3201\/eid0908.030069","article-title":"Candidemia in Finland, 1995\u20131999","volume":"9","author":"Poikonen","year":"2003","journal-title":"Emerg Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib18","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1128\/JCM.00029-06","article-title":"Candidemia in Norway (1991 to 2003): results from a nationwide study","volume":"44","author":"Sandven","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib19","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/13693780701200372","article-title":"Fungal infections in solid organ transplantation","volume":"45","author":"Silveira","year":"2007","journal-title":"Med Mycol"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib20","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(03)00801-6","article-title":"Epidemiology of Candida species infections in critically ill non-immunosuppressed patients","volume":"3","author":"Eggimann","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib21","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1097\/CCM.0b013e31819efac0","article-title":"Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005\u20132006)","volume":"37","author":"Leroy","year":"2009","journal-title":"Crit Care Med"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib22","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s00134-007-0865-y","article-title":"CandiRea Study Group. Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome","volume":"34","author":"Bougnoux","year":"2008","journal-title":"Intensive Care Med"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib23","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jinf.2009.08.020","article-title":"Excess mortality, length of stay and cost attributable to candidaemia","volume":"59","author":"Hassan","year":"2009","journal-title":"J Infect"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib24","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1086\/378745","article-title":"Attributable mortality of nosocomial candidemia, revisited","volume":"37","author":"Gudlaugsson","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib25","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1517\/14656566.8.11.1643","article-title":"Candidemia in the in-patient setting: treatment options and economics","volume":"8","author":"Gagne","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib26","first-page":"586","article-title":"Costs associated with candidemia in a hospital setting","volume":"31","author":"Gagne","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib27","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1086\/496922","article-title":"The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis","volume":"41","author":"Zaoutis","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib28","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1086\/514955","article-title":"The impact of candidemia on length of hospital stay, outcome, and overall cost of illness","volume":"27","author":"Rentz","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib29","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1128\/JCM.43.11.5425-5427.2005","article-title":"In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole","volume":"43","author":"Pfaller","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib30","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1128\/JCM.43.12.5848-5859.2005","article-title":"Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing","volume":"43","author":"Pfaller","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib31","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3109\/13693780903580121","article-title":"Five-year evaluation of bloodstream yeast infections in a tertiary hospital: the predominance of non-C. albicans Candida species","volume":"48","author":"Pereira","year":"2010","journal-title":"Med Mycol"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib32","first-page":"1732","article-title":"Overview of the changing epidemiology of candidemia","volume":"25","author":"Lewis","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib33","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1128\/JCM.44.5.1782-1787.2006","article-title":"International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003)","volume":"44","author":"Messer","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib34","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1128\/AAC.00945-09","article-title":"The effect of antifungal timing on mortality in cancer patients with candidemia","volume":"54","author":"Taur","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib35","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/jac\/dkm212","article-title":"Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections","volume":"60","author":"Parkins","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib36","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1128\/AAC.49.9.3640-3645.2005","article-title":"Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality","volume":"49","author":"Morrell","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib37","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1086\/504810","article-title":"Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study","volume":"43","author":"Garey","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib38","doi-asserted-by":"crossref","first-page":"R156","DOI":"10.1186\/cc8110","article-title":"Candidemia on presentation to the hospital: development and validation of a risk score","volume":"13","author":"Shorr","year":"2009","journal-title":"Crit Care"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib39","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s00134-005-2794-y","article-title":"Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis","volume":"31","author":"Cruciani","year":"2005","journal-title":"Intensive Care Med"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib40","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1097\/CCM.0b013e31819dec9b","article-title":"Evolving role of early antifungals in the adult intensive care unit","volume":"37","author":"Lam","year":"2009","journal-title":"Crit Care Med"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib41","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1007\/s11908-008-0074-z","article-title":"Invasive candidiasis in the ICU: prophylaxis versus preemptive treatment","volume":"10","author":"Rotstein","year":"2008","journal-title":"Curr Infect Dis Rep"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib42","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s00134-008-1339-6","article-title":"Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: part II. Treatment","volume":"35","author":"Guery","year":"2009","journal-title":"Intensive Care Med"},{"issue":"suppl 1","key":"10.1111\/j.1469-0691.2010.03448.x_bib43","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2165\/11315540-000000000-00000","article-title":"Antifungal prophylaxis and pre-emptive therapy","volume":"69","author":"Viscoli","year":"2009","journal-title":"Drugs"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib44","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1007\/s00134-009-1623-0","article-title":"Mart\u00edn E. Serum procalcitonin levels in critically ill patients colonized with Candida spp: new clues for the early recognition of invasive candidiasis","volume":"35","author":"Charles","year":"2009","journal-title":"Intensive Care Med"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib45","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1097\/CCM.0b013e31819daa14","article-title":"Usefulness of the \u2018Candida score\u2019 for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study","volume":"37","author":"Le\u00f3n","year":"2009","journal-title":"Crit Care Med"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib46","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1586\/eri.09.104","article-title":"PCR-based diagnosis of human fungal infections","volume":"7","author":"Khot","year":"2009","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib47","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1439-0507.2009.01732.x","article-title":"Current diagnostic approaches to invasive candidiasis in critical care settings","volume":"53","author":"Pem\u00e1n","year":"2010","journal-title":"Mycoses"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib48","doi-asserted-by":"crossref","first-page":"83","DOI":"10.7326\/0003-4819-149-2-200807150-00004","article-title":"Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial","volume":"149","author":"Schuster","year":"2008","journal-title":"Ann Intern Med"},{"issue":"suppl 1","key":"10.1111\/j.1469-0691.2010.03448.x_bib58","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2165\/11315560-000000000-00000","article-title":"Anidulafungin, a new echinocandin: in vitro activity","volume":"69","author":"Morace","year":"2009","journal-title":"Drugs"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib59","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1128\/JCM.00942-09","article-title":"In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods","volume":"47","author":"Diekema","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib60","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1128\/JCM.01901-07","article-title":"In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance","volume":"46","author":"Pfaller","year":"2008","journal-title":"J Clin Microbiol"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib61","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/jac\/46.3.475","article-title":"Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B","volume":"46","author":"Cuenca-Estrella","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib62","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1056\/NEJMoa066906","article-title":"Anidulafungin versus fluconazole for invasive candidiasis","volume":"356","author":"Reboli","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib63","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1592\/phco.27.3.369","article-title":"The echinocandins","volume":"27","author":"Cappelletty","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib64","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1128\/JCM.44.3.760-763.2006","article-title":"In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance","volume":"44","author":"Pfaller","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib65","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1469-0691.2008.02660.x","article-title":"Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit","volume":"15","author":"Ghannoum","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib66","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1056\/NEJMe020142","article-title":"Echinocandins\u2013an advance in the primary treatment of invasive candidiasis","volume":"347","author":"Walsh","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib67","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1056\/NEJMct060052","article-title":"Echinocandins for candidemia in adults without neutropenia","volume":"355","author":"Bennett","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib68","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1128\/JCM.00566-08","article-title":"Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints","volume":"46","author":"Pfaller","year":"2008","journal-title":"J Clin Microbiol"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib69","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1128\/AAC.49.11.4795-4797.2005","article-title":"Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis","volume":"49","author":"Pfaller","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib70","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s10096-009-0843-0","article-title":"Factors related to survival and treatment success in invasive candidiasis or candidemia: a pooled analysis of two large, prospective, micafungin trials","volume":"29","author":"Horn","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib71","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1128\/AAC.00211-08","article-title":"In vitro activity of anidulafungin against Candida albicans biofilms","volume":"52","author":"Jacobson","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib72","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1128\/AAC.00856-07","article-title":"Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms","volume":"52","author":"Katragkou","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib73","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1128\/AAC.44.4.1108-1111.2000","article-title":"Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans","volume":"44","author":"Ernst","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib74","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1128\/AAC.00095-07","article-title":"Paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandin-specific and Candida species-related differences","volume":"5","author":"Chamilos","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib75","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10096-007-0411-4","article-title":"Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis","volume":"27","author":"Fleischhacker","year":"2008","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib76","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1177\/0091270004265644","article-title":"Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal","volume":"44","author":"Dowell","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib78","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1128\/AAC.01279-08","article-title":"In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin","volume":"53","author":"Damle","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib79","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1177\/0091270006297227","article-title":"Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment","volume":"47","author":"Dowell","year":"2007","journal-title":"J Clin Pharmacol"},{"issue":"suppl 14","key":"10.1111\/j.1469-0691.2010.03448.x_bib80","first-page":"35","article-title":"Role of anidulafungin in critically ill patients","volume":"26","author":"Borges","year":"2008","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib81","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000096348","article-title":"The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications","volume":"78","author":"Wagner","year":"2006","journal-title":"Pharmacology"},{"issue":"suppl 1","key":"10.1111\/j.1469-0691.2010.03448.x_bib82","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1439-0507.2007.01378.x","article-title":"Anidulafungin\u2014state of affairs from a clinical perspective","volume":"50","author":"Vehreschild","year":"2007","journal-title":"Mycoses"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib83","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1128\/AAC.48.6.2021-2024.2004","article-title":"Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia","volume":"48","author":"Krause","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib84","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa021585","article-title":"Comparison of caspofungin and amphotericin B for invasive candidiasis","volume":"347","author":"Mora-Duarte","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib85","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(07)60605-9","article-title":"Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial","volume":"369","author":"Kuse","year":"2007","journal-title":"Lancet"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib86","doi-asserted-by":"crossref","first-page":"R159","DOI":"10.1186\/cc8117","article-title":"Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B","volume":"13","author":"Dupont","year":"2009","journal-title":"Crit Care"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib87","unstructured":"Reboli, AC., Rotsteinm, C., Kett, DH, et al. Resource utilisation and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients. Pharmacoeconomics, [in press]."},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib88","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s001340050286","article-title":"Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU","volume":"23","author":"Nolla-Salas","year":"1997","journal-title":"Intensive Care Med"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib89","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.4065\/83.9.1011","article-title":"Treatment of invasive candidal infections: systematic review and meta-analysis","volume":"83","author":"Gafter-Gvili","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"suppl 1","key":"10.1111\/j.1469-0691.2010.03448.x_bib90","doi-asserted-by":"crossref","first-page":"P72","DOI":"10.1186\/cc8304","article-title":"Anidulafungin compared with fluconazole therapy in critically ill patients","volume":"14","author":"Kett","year":"2010","journal-title":"Crit Care"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib91","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1128\/AAC.50.2.632-638.2006","article-title":"Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections","volume":"50","author":"Benjamin","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib92","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1592\/phco.28.1.64","article-title":"Early clinical experience with anidulafungin at a large tertiary care medical center","volume":"28","author":"Brielmaier","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib93","article-title":"European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3\u20132009 Update","author":"Maertens","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1111\/j.1469-0691.2010.03448.x_bib94","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ijantimicag.2009.03.003","article-title":"Extended daily dialysis does not affect the pharmacokinetics of anidulafungin","volume":"34","author":"Burkhardt","year":"2009","journal-title":"Int J Antimicrob Agents"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14606625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14606625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:12:48Z","timestamp":1761117168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X14606625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":84,"alternative-id":["S1198743X14606625"],"URL":"https:\/\/doi.org\/10.1111\/j.1469-0691.2010.03448.x","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anidulafungin for the treatment of invasive candidiasis","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1469-0691.2010.03448.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 European Society of Clinical Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}